Manuscripts: research articles, editorials, etc

cropped-cropped-bacils1.jpgPUBLICATIONS (SCIENTIFIC PAPERS)


101. Cardona, Pere-Joan ;Prats, Clara. The Small Breathing Amplitude at the Upper Lobes Favors the Attraction of Polymorphonuclear Neutrophils to Mycobacterium tuberculosis Lesions and Helps to Understand the Evolution toward Active Disease in An Individual-Based Model. Frontiers in microbiology. 2016 March 29. doi:  10.3389/fmicb.2016.00354

100. Zumla, Alimuddin ;Rao, Martin ;Wallis, Robert S ;Kaufmann, Stefan H E ;Rustomjee, Roxana ;Mwaba, Peter ;Vilaplana, Cris ;Yeboah Manu, Dorothy ;Chakaya, Jeremiah ;Ippolito, Giuseppe ;Azhar, Esam ;Hoelscher, Michael ;Maeurer, Markus. Host-directed therapies for infectious diseases current status recent progress and future prospects. The Lancet Infectious diseases. 2016 April.

99. Clara Prats; Cristina Vilaplana; Joaquim Valls; Elena Marzo; Pere-Joan Cardona; Daniel López. Local Inflammation, Dissemination and Coalescence of Lesions Are Key for the Progression toward Active Tuberculosis: The Bubble Model. Frontiers in Microbiology. 2016 February 02.

98. Prats, Clara ;Montañola-Sales, Cristina ;Gilabert-Navarro, Joan F. ;Valls, Joaquim ;Casanovas-García, Josep ;Vilaplana, Cristina ;Cardona, Pere-Joan ;López, Daniel. Individual-Based Modeling of Tuberculosis in a User-Friendly Interface: Understanding the Epidemiological Role of Population Heterogeneity in a City. Frontiers in Microbiology. 2016 January 12. doi: 10.3389/fmicb.2015.01564

97. Cardona, Paula ;Marzo-Escartín, Elena ;Tapia, Gustavo ;Díaz, Jorge ;García, Vanessa ;Varela, Ismael ;Vilaplana, Cristina ;Cardona, Pere-Joan. Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice. Frontiers in Microbiology. 2016 January 5.


96. Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D’Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S102-S118.

95. Alimuddin Zumla, Markus Maeurer and the Host-Directed Therapies Network (HDT-NET) ConsortiumHost-Directed Therapies for tackling Multi-Drug Resistant TB – learning from the Pasteur-Bechamp debates. Clin Infect Dis. 2015 Jul 28. pii: civ631

94. Alimuddin ZumlaJeremiah ChakayaMichael HoelscherFrancine Ntoumi,Roxana RustomjeeCristina VilaplanaDorothy Yeboah-ManuVoahangy RasolofPaula Munderi et al. Towards host-directed therapies for tuberculosis. Nature Reviews Drug Discovery (2015). doi:10.1038/nrd4696

93. P-J Cardona. 2015 June 16. The key role of exudative lesions and their encapsulation: Lessons learned from the pathology of human pulmonary tuberculosis. Frontiers in Microbiology 6:612. USA.

92. Peter Sander, Simon Clark, Agnese Petrera, Cristina Vilaplana, Michael Meulia,Petra Selchowa, Andrea Zelmere, Deepa Mohananf, Nuria Andreue, Emma Raynerc,Michael Dal Molina, Gregory J. Bancrofte, Pål Johansenf, Pere-Joan Cardona,Ann Williamsc, Erik C. Böttgera. 2015 Feb 5. Deletion of zmp1 improves Mycobacterium bovis BCG-mediatedprotection in a guinea pig model of tuberculosisdoi.org10.1016j.vaccine.2015.01.058.

91Rech G, Vilaplana  CVelasco J, Pluvinet R, Santín SPrat CJulián EAlcaide FComas ISumoy L, Cardona PJ. Draft Genome Sequences of Mycobacterium setense Type Strain DSM- 45070 and the Nonpathogenic Strain Manresensis, Isolated from the Bank of the Cardener River in Manresa, Catalonia, Spain. Genome Announc3(1):e0148514. doi:10.1128/genomeA.01485-14. 2015 Feb 5.


90. Vilaplana C, Prats C, Marzo E, Barril C, Vegué M, et al. (2014) To Achieve an Earlier IFN-γ Response Is Not Sufficient to Control Mycobacterium tuberculosis Infection in Mice. PLoS ONE 9(6): e100830. doi:10.1371/journal.pone.0100830

89. Cardona PJ, Vilaplana C. Multiple Consecutive Infections Might Explain the Lack of Protection by BCG. PLoS One. 2014 Apr 16;9(4):e94736. doi:10.1371/journal.pone.0094736. eCollection 2014.

88. Nell AS, D’lom E, Bouic P, Sabaté M, Bosser R, Picas J, Amat M, Churchyard G, Cardona PJ. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014 Feb 26;9(2):e89612. doi:10.1371/journal.pone.0089612. eCollection 2014.

88. Ruiz Manzano J, Vilaplana C. ¿Trataremos la tuberculosis con vacunas en el siglo xxi?Arch Bronconeumol. 2014.

87. Gröschel MI, Prabowo SA, Cardona PJ, Stanford JL, Werf TS. Therapeutic vaccines for tuberculosis-A systematic review.Vaccine. 2014 Apr 8. pii: S0264-410X(14)00416-2. doi: 10.1016/j.vaccine.2014.03.047. [Epub ahead of print]

86. Vilaplana C and Cardona P-J (2014) The lack of a big picture in tuberculosis: the clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies. Front. Microbiol. 5:55. doi: 10.3389/fmicb.2014.00055 The lack of a big picture in tuberculosis


85. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Marzo E, Vilaplana C, Tapia G, Diaz J, Garcia V, Cardona PJ. Tuberculosis. Available online 19 September 2013, ISSN 1472-9792,

84.  The Scavenger Protein Apoptosis Inhibitor of Macrophages (AIM) Potentiates the Antimicrobial Response against Mycobacterium tuberculosis by Enhancing Autophagy. Sanjurjo L, Amézaga N, Vilaplana C, Cáceres N, Marzo E, Valeri M, Cardona P-J, Sarrias M-R. PLoS ONE 8(11): e79670. doi:10.1371/journal.pone.0079670.

83. Construction, characterization and preclinical evaluation of MTBVAC, the firstlive-attenuated M.tuberculosis-based vaccine to enter clinical trials. Arbues A, Aguilo J I, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. Vaccine. 2013 Aug 17. doi:pii: S0264-410X(13)01008-6. 10.1016/j.vaccine.2013.07.051. [Epub ahead of print]

82. Evolution and role of corded cell aggregation in M.tuberculosis cultures. Caceres N, Vilaplana C,   Prats C, Marzo E,  Llopis I,  Valls J,   Lopez D, Cardona PJ. Tuberculosis (Edinb). 2013 Aug 13. doi:pii: S1472-9792(13)00152-2. 10.1016/ [Epub ahead of print]

81. Ibuprofen is able to reduce the lung pathology, to decrease bacillary load in tissues and to increase survival in a new murine experimental model of active tuberculosis. Cristina Vilaplana; Elena Marzo; Gustavo Tapia; Jorge Diaz; Vanesa Garcia; Pere-Joan Cardona. J Infect Dis. 2013 Jul 15;208(2):199-202. doi: 10.1093/infdis/jit152. Epub 2013 Apr 5.

80. Selected culture and drug susceptibility testing methods for drug-resistant Mycobacterium tuberculosis screening in resurce-constrained settings. Ausina V, Fernandez G, Vilaplana C. Expert Rev Mol Diagn, April 2013, Vol. 13, No. 3, Pages 247-249

79. Chemo-enzymatic synthesis and glycosidase inhibitory properties of DAB and LAB derivatives. Concia AL, Gomez L, Bujons J, Parella T, Vilaplana C, Cardona PJ, Joglar J, Clapés P. Org. Biomol. Chem., 2013, 11 (12), 2005 – 2021


78. A two-compartment system allows lymphatic tissues to control M. tuberculosis infection in the peripheral organs.  Vilaplana C, Prats C, Marzo E, Barril C, Llopis I, Diaz J, Valls Q, Lopez D, Cardona PJ. Immunology 2012, 137, Supp 1: 595-596

77. The Scavenger protein Spalpha modulates the macrophage response to Mycobacterium tuberculosis. Sanjurjo, L., Amezaga, N., Vilaplana C, Caceres N, Marzo E, Cardona PJ, Sarrias MR.  Immunology 2012, 137, Supp 1: 149-149

76. Chemoenzymatic synthesis, structural study and biological activity of novel indolizidine and quinolizidine iminocyclitols. L Gómez, X Garrambou, J Joglar, J Bujons, T Parella, C Vilaplana, PJ Cardona, P Clapés. Org. Biomol. Chem., 2012, 10 (31), 6309 -6321

75. Pere-Joan Cardona (2012). Ten Questions to Challenge the Natural History of Tuberculosis, Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-942-4, InTech, DOI: 10.5772/30247.

74.Cristina Vilaplana and Pere-Joan Cardona (2012). The Hidden History of Tuberculin, Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-942-4, InTech, DOI: 10.5772/31218.

73. Caceres N,  Llopis I, Marzo E, Prats C, Vilaplana C, Garcia de Viedma D, Samper S, Lopez D, Cardona PJ. Low Dose Aerosol Fitness at the Innate Phase of Murine Infection Better Predicts Virulence amongst Clinical Strains of Mycobacterium tuberculosis. PLoS One. 2012;7(1):e29010. Epub 2012 Jan 3 10.1371/journal.pone.0029010.

72. Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis. Edited by Pere-Joan Cardona, ISBN 978-953-307-938-7, Hard cover, 552 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license. DOI: 10.5772/1483

71. Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance. Edited by Pere-Joan Cardona, ISBN 978-953-307-948-6, Hard cover, 376 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license. DOI: 10.5772/247

70. Understanding Tuberculosis – Deciphering the Secret Life of the Bacilli. Edited by Pere-Joan Cardona, ISBN 978-953-307-946-2, Hard cover, 334 pages, Publisher: InTech, Chapters published February 17, 2012 under CC BY 3.0 license. DOI: 10.5772/2479

69. Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity. Edited by Pere-Joan Cardona, ISBN 978-953-307-942-4, Hard cover, 560 pages, Publisher: InTech, Chapters published February 24, 2012 under CC BY 3.0 license. DOI: 10.5772/2478


68. Guio H, Vilaplana C, Cardona PJ. 2011.Inmunodiagnosis and Biomarkers in Tuberculosis. 2011 Oct 8;137(9):408-413. Epub 2010 Nov 5. Spanish. PMID:21056436

67. Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, Dolganov G, Schoolnik G K., Cassidy J, Billeskov R, Andersen P. 2011. A multistage tuberculosis vaccine that confers efficient protection pre– and post–exposure. Nat Med. 2011 Feb;17(2):189-94. Epub 2011 Jan 23. PMID: 21258338 Aagard_NatMed_2011_H56

66. Cardona PJ, Ivanyi Juraj. The secret trumps, impelling the pathogenicity of tubercle bcilli. Enferm Infecc Microbiol Clin, 2011; 29 (Supl 1): 14-19. Cardona et Ivanyi EIMC 2011 TB Cycle

65. Cardona PJ. A spotlight on Liquefaction: Evidence from Clinical Settings and Experimental Models in Tuberculosis. Clin Dev Immunol. 2011;2011:868246. Epub 2011 Mar 13. Review. PMID:21437230. CardonaCDI_2011_Liquefaction

64. Pérez de Val B, López-Soria S, Nofrarías M, Martín M, Vordermeier MH, Villarreal-Ramos B, Romera N, Escobar M, Solanes D, Cardona PJ, Domingo M. Experimental model of tuberculosis in the domestic goat after endobronchial infection with Mycobacterium caprae. Clin Vaccine Immunol. 2011 Aug 31. [Epub ahead of print] PMID:21880849 Clinical and Vaccine Immunology_cresa_2011

63. Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona PJ.  Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One. 2011;6(5):e20404. Epub 2011 May 24. PMID:21647222.

62. Saubi N, Im EJ, Fernández-Lloris R, Gil O, Cardona PJ, Gatell JM, Hanke T, Joseph J. Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol. 2011;2011:516219. Epub 2011 Apr 12. PMID:21603216 Clinical and Developmental Immunology. 2011_Gatell_JoJo_PJ


61. Vilaplana, C., Montane, E., Pinto, S., Barriocanal, A. M., Domenech, G., Torres, F., Cardona, P. J. & Costa, J. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28, 1106-1116. Vilaplana Vaccine 2010 Phase I CT of RUTI

60. Vilaplana, C. & Cardona, P. J. Tuberculin immunotherapy: its history and lessons to be learned. Microbes Infect 12, 99-105. Vilaplana MIC 2010 Tuberculin treatment history

59. Cardona, P. J. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch Immunol Ther Exp (Warsz) 58, 7-14. Cardona Revisiting Natural History 2010

58. Rullas, J., Garcia, J. I., Beltran, M., Cardona, P. J., Caceres, N., Garcia-Bustos, J. F. & Angulo-Barturen, I. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54, 2262-2264.

57. Gil, O., Diaz, I., Vilaplana, C., Tapia, G., Diaz, J., Fort, M., Caceres, N., Pinto, S., Cayla, J., Corner, L., Domingo, M. & Cardona, P. J. Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS One 5, e10030.

56. Joseph J, Fernández-Lloris R, Pezzat E, Saubi N, Cardona PJ, Mothe B, Gatell JM.Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors. J Biomed Biotechnol. 2010;2010:357370. Epub 2010 Jun 27.

55. Bru A, Cardona P-J, 2010 Mathematical Modeling of Tuberculosis Bacillary Counts and Cellular Populations in the Organs of Infected Mice. PLoS ONE 5(9): e12985. doi:10.1371/journal.pone.0012985.

54. Cardona PJ (2010). Therapeutic vaccines. – The art and science of TB vaccine development.  Edited by Norazmi MN, Acosta A, Sarmiento ME.  Malaysia Oxford Fajar. ebook:


53. Cáceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, Vilaplana C, Cardona PJ. “Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models”. Tuberculosis (Edinb). 2009 March (89); 175-182. Caceres, Tuberculosis 2009, Foamies’ evolution

52. Cardona P-J. A dynamic reinfection hypothesis of latent  tuberculosis infection. Infection 2009. 37:80-86 Cardona, Infection 2009, Dynamic hypothesis

51. Cardona PJ, Asensio JG, Arbues A, Otal I, Lafoz C, Gil O, et al. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 2009;27(18):2499-505.

50. Domingo M, Gil O, Serrano E, Guirado E, Nofrarias M, Grassa M, Caceres N, Perez B, Vilaplana C, Cardona PJ. Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells’ fragments: fiel-study with naturally Mycobacterium caprae-infected goats. Scand J Immunol 2009 April 69: 500-507. Domingo SJI_2009_TB-Goat_RUTI

49. Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S. & Altare, F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009; 10, 943-948.


48. Rodríguez-Güell E, Agustí G, Corominas M, Cardona PJ, Luquin M, Julián E. “Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton”. Clin Vaccine Immunol. 2008 May;15(5):893-6.

47. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, Singh M, Spallek R, Ausina V, Cardona PJ. “The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays”. Scand J Immunol. 2008 Jun;67(6):610-7. TST, Vilaplana 2008

46. Guirado E, Gil O, Cáceres N, Singh M, Vilaplana C, Cardona PJ. “Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis”. Clin Vaccine Immunol. 2008 Aug;15(8):1229-37. Guirado, CVI 2008

45. Di Liberto D, Locati M, Caccamo N, Vecchi A, Meraviglia S, Salerno A, Sireci G, Nebuloni M, Caceres N, Cardona PJ, Dieli F, Mantovani A. “Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection”. J Exp Med. 2008 Sep 1;205(9):2075-84.

44. Cardona PJ. “Should an immunosuppressed patient with a positive TIGRA test and a negative PPD test be treated?”. Med Clin (Barc). 2008 May 31;130(20):776-7. Erratum in: Med Clin (Barc). 2008 Oct 25;131(14):525.                                                                          

43. Gil O, Vilaplana C, Guirado E, Díaz J, Cáceres N, Singh M, Cardona PJ. “Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse”.  Clin Vaccine Immunol. 2008 Nov;15(11):1742-4. Gil_CVI_2008_IP model for RUTI

42. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. “Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence”.PLoS Pathog. 2008. Nov;4(11):e1000204.


41. Cardona PJ. “Robert Koch was right. Towards a new interpretation of tuberculin therapy”. Enferm Infecc Microbiol Clin. 2006 Jun-Jul;24(6):385-91. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2007 Feb;25(2):81. Robert Koch Was Right

40. Cardona PJ. “New insights on the nature of latent tuberculosis infection and its treatment”. Inflamm Allergy Drug Targets. 2007 Mar;6(1):27-39. New Insights, Inflammation 2007

39. Nobrega C, Cardona PJ, Roque S, Pinto do O P, Appelberg R, Correia-Neves M. “The thymus as a target for mycobacterial infections”. Microbes Infect. 2007 Nov-Dec;9(14-15):1521-9.

38. Cardona PJ. “Therapeutic vaccines against tuberculosis: a glowing future”. Arch Bronconeumol. 2007 Nov;43(11):591-3. Vaccines TB, Glowing Future, Cardona


37. Cardona PJ, Soto CY, Martín C, Giquel B, Agustí G, Andreu N, Guirado E, Sirakova T, Kolattukudy P, Julián E, Luquin M. “Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis”. Microbes Infect. 2006 Jan;8(1):183-90. Epub 2005 Aug 10. Erratum in: Microbes Infect. 2006 Sep;8(11):2668. Andreu, Núria [added]. Cardona, Neutral_red Reaction_& virulence, _MicInfect 2006

36. Gil O, Guirado E, Gordillo S, Díaz J, Tapia G, Vilaplana C, Ariza A, Ausina V, Cardona PJ. “ Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type”. Microbes Infect. 2006 Mar;8(3):628-36. Gil, Intragranulomatous Necrosis, MicInfec 2006

35. Cardona PJ. “RUTI: a new chance to shorten the treatment of latent tuberculosis infection”.Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89. RUTI New Chance

34. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B. “The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs”. Vaccine. 2006 Apr 24;24(17):3408-19.

33. Tjärnlund A, Rodríguez A, Cardona PJ, Guirado E, Ivanyi J, Singh M, Troye-Blomberg M, Fernández C. “Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice”. Int Immunol. 2006 May;18(5):807-16.

32. Guirado E, Gordillo S, Gil O, Díaz J, Tapia G, Vilaplana C, Ausina V, Cardona PJ. “Intragranulomatous necrosis in pulmonary granulomas is not related to resistance against Mycobacterium tuberculosis infection in experimental murine models induced by aerosol”. Int J Exp Pathol. 2006 Apr;87(2):139-49. Guirado, Intragranulomatous Necrosis, IntJExpPath 2006

31. Rodríguez-Güell E, Agustí G, Corominas M, Cardona PJ, Casals I, Parella T, Sempere MA, Luquin M, Julián E. “The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production”. Antonie Van Leeuwenhoek. 2006 Jul;90(1):93-108.

30. Guirado E, Amat I, Gil O, Díaz J, Arcos V, Caceres N, Ausina V, Cardona PJ. “Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice”. Microbes Infect. 2006 Apr;8(5):1252-9. Guirado, Passive Serum Therapy, MicInfect 2006

29. Gordillo S, Guirado E, Gil O, Díaz J, Amat I, Molinos S, Vilaplana C, Ausina V, Cardona PJ. “Usefulness of acr expression for monitoring latent Mycobacterium tuberculosis bacilli in ‘in vitro’ and ‘in vivo’ experimental models”. Scand J Immunol. 2006 Jul;64(1):30-9. Gordillo, in Vitro-inVivo, Scand 2006

28. Tjärnlund A, Guirado E, Julián E, Cardona PJ, Fernández C. “Determinant role for Toll-like receptor signalling in acute mycobacterial infection in the respiratory tract”. Microbes Infect. 2006 Jun;8(7):1790-800. Tjarnlund, MicrobesInfect 2006

27. Cardona PJ, Amat I. “Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection”. Arch Bronconeumol. 2006 Jan;42(1):25-32. RUTI Origin, Cardona & Amat

26. Cardona PJ. “Mycobacterium tuberculosis and Homo sapiens: a long road to cross”. Med Clin (Barc). 2006 May 27;126(20):771-3. Mtb & homo Sapiens, MedClin 2006


25. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, Vilaplana C, Tapia G, Ausina V. “Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis”. Vaccine. 2005 Feb 3;23(11):1393-8. RUTI Vaccine 2005

24. Garcia de Viedma D, Lorenzo G, Cardona PJ, Rodriguez NA, Gordillo S, Serrano MJ, Bouza E. “Association between the infectivity of Mycobacterium tuberculosis strains and their efficiency for extrarespiratory infection”. J Infect Dis. 2005 Dec 15;192(12):2059-65. Garcia de Viedma: Association Between Infectivity, JID2005


23. Cardona PJ, Ruiz-Manzano J. “On the nature of Mycobacterium tuberculosis-latent bacilli”. Eur Respir J. 2004 Dec;24(6):1044-51. On The Nature Latent Bacilli_EurJRespir 2004


22. Cardona PJ, Gordillo S, Díaz J, Tapia G, Amat I, Pallarés A, Vilaplana C, Ariza A, Ausina V. “Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis”. Infect Immun. 2003 Oct;71(10):5845-54. Widespread Bronchogenic Dissemination InfImm 2003

21. Cardona PJ. “Advantages and limitations of experimental animal models for the study of infectious diseases”. Enferm Infecc Microbiol Clin. 2003 Aug-Sep;21(7):327-8.

20. Cardona PJ, Gordillo S, Amat I, Díaz J, Lonca J, Vilaplana C, Pallarés A, Llatjós R, Ariza A, Ausina V. “Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis”. Tuberculosis (Edinb). 2003;83(6):351-9.                                                  


19. Cardona PJ, Julián E, Vallès X, Gordillo S, Muñoz M, Luquin M, Ausina V. “Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis”. Scand J Immunol. 2002 Jun;55(6):639-45.


18. Cardona PJ, Llatjós R, Gordillo S, Díaz J, Viñado B, Ariza A, Ausina V. “Towards a ‘human-like’ model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis”. Scand J Immunol. 2001 Jan;53(1):65-71.


17. Cardona PJ, Ausina V. “Delayed-type hypersensitivity and caseous necrosis in tuberculous granuloma. New ideas for the design of a new vaccine against human tuberculosis”. Med Clin (Barc). 2000 Oct 21;115(13):503-9.

16. Cardona PJ, Llatjós R, Gordillo S, Díaz J, Ojanguren I, Ariza A, Ausina V. “Evolution of granulomas in lungs of mice infected aerogenically with Mycobacterium tuberculosis”. Scand J Immunol. 2000 Aug;52(2):156-63.

15. Cardona PJ, Ausina V. “Histopathology of tuberculosis. Approximation to the clinical course of lung lesions in animal experimentation models induced with aerosols.” Arch Bronconeumol.2000 Dec;36(11):645-50.


14. Monsó E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, Morera J. “Risk factors for lower airway bacterial colonization in chronic bronchitis”. Eur Respir J. 1999 Feb;13(2):338-42.

13. Cardona PJ, Cooper A, Luquín M, Ariza A, Filipo F, Orme IM, Ausina V. “The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity”. Scand J Immunol. 1999 Apr;49(4):362-6


12. Gamboa F, Fernandez G, Padilla E, Manterola JM, Lonca J, Cardona PJ, Matas L, Ausina V. “Comparative evaluation of initial and new versions of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens”. J Clin Microbiol. 1998 Mar;36(3):684-9.

11. Gamboa F, Dominguez J, Padilla E, Manterola JM, Gazapo E, Lonca J, Matas L, Hernandez A, Cardona PJ, Ausina V. “Rapid diagnosis of extrapulmonary tuberculosis by ligase chain reaction amplification”. J Clin Microbiol. 1998 May;36(5):1324-9.

10. Gamboa F, Manterola JM, Lonca J, Matas L, Cardona PJ, Padilla E, Viñado B, Domínguez J, Hernández A, Ausina V. “Comparative evaluation of two commercial assays for direct detection of Mycobacterium tuberculosis in respiratory specimens.” Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):151-7.

9. Gamboa F, Cardona PJ, Manterola JM, Lonca J, Matas L, Padilla E, Manzano JR, Ausina V. “Evaluation of a commercial probe assay for detection of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and nonrespiratory clinical samples”. Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):189-92.

8. Matas L, Domínguez J, De Ory F, García N, Galí N, Cardona PJ, Hernández A, Rodrigo C, Ausina V. “Evaluation of Meridian ImmunoCard Mycoplasma test for the detection of Mycoplasma pneumoniae-specific IgM in paediatric patients”. Scand J Infect Dis. 1998;30(3):289-93.

7. Manterola JM, Gamboa F, Padilla E, Lonca J, Matas L, Hernández A, Giménez M, Cardona PJ, Viñado B, Ausina V. “Comparison of a nonradiometric system with Bactec 12B and culture on egg-based media for recovery of mycobacteria from clinical specimens”. Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):773-7.


6. Gamboa F, Manterola JM, Viñado B, Matas L, Giménez M, Lonca J, Manzano JR, Rodrigo C, Cardona PJ, Padilla E, Domínguez J, Ausina V. “Direct detection of Mycobacterium tuberculosis complex in nonrespiratory specimens by Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test”. J Clin Microbiol. 1997 Jan;35(1):307-10. Erratum in: J Clin Microbiol 1998 Sep;36(9):2801.

5. Ausina V, Gamboa F, Gazapo E, Manterola JM, Lonca J, Matas L, Manzano JR, Rodrigo C, Cardona PJ, Padilla E. “Evaluation of the semiautomated Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis in respiratory specimens”. J Clin Microbiol. 1997 Aug;35(8):1996-2002.

4. Gamboa F, Manterola JM, Lonca J, Matas L, Viñado B, Giménez M, Cardona PJ, Padilla E, Ausina V. “Detection and identification of mycobacteria by amplification of RNA and DNA in pretreated blood and bone marrow aspirates by a simple lysis method”. J Clin Microbiol. 1997 Aug;35(8):2124-8.

3. Gamboa F, Manterola JM, Lonca J, Viñado B, Matas L, Giménez M, Manzano JR, Rodrigo C, Cardona PJ, Padilla E, Dominguez J, Ausina V. “Rapid detection of Mycobacterium tuberculosis in respiratory specimens, blood and other non-respiratory specimens by amplification of rRNA”. Int J Tuberc Lung Dis. 1997 Dec;1(6):542-55.


2. Gavaldà J, Cardona PJ, Almirante B, Capdevila JA, Laguarda M, Pou L, Crespo E,   Pigrau C, Pahissa A. “Treatment of experimental endocarditis due to Enterococcus       faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of   ampicillin in human serum.”. Antimicrob Agents Chemother. 1996 Jan;40(1):173-8.

1. Giménez M, Sopena N, Viñado B, Cardona PJ, Pedro-Botet ML, Coroleu W, Arnal J. “Invasive Streptococcus agalactiae infections at a general university hospital over a 10-year period”. Enferm Infecc Microbiol Clin. 1996 May;14(5):300-3.